Liquiritiae radix

Authors: Prof. Dr. med. Peter Altmeyer, Prof. Dr. med. Martina Bacharach-Buhles

All authors of this article

Last updated on: 06.01.2022

Dieser Artikel auf Deutsch


Glycyrrhiza glabra; Licorice; Licorice root; Radix liquiritiae. Liquorice root

This section has been translated automatically.

Liquorice root, drug obtained from the unpeeled or peeled dried root of Glycyrrhiza glabra the liquorice shrub. There are positive monographs of the Commission E and the ESCOP.

Active ingredients are: 2-15% glycyrrhizin (according to PH.Eur. at least 4% of dry weight), glycyrrhetinic acid, mannitol, glucose, sucrose, flavone glycosides (e.g. liquiritin).


HMPC monograph: Traditional-use: dyspeptic complaints, heartburn, expectorant in cold-related coughESCOP monograph
: gastric and duodenal ulcers, gastritis; expectorant in cough and bronchial catarrh.
Commission E monograph: Upper respiratory tract catarrh, ventriculi/duodeni ulcer.

Field of application/use
This section has been translated automatically.

Dyspeptic complaints, heartburn, mucolytic agent in cold-related cough, bronchitis, ulcus ventriculi/duodeni, aphthae.

An extract of licorice can also be used successfully for chloasma.

Externally, as an ointment significant improvement of erythema, edema and pruritus (double-blind, placebo-controlled study; Abramowitz et al) Commercial preparation: Atopiclair®.

Dosage and method of use
This section has been translated automatically.

Average daily dose: approx. 5-15 g of drug corresponding to 200-800 mg of glycyrrhizin; Succus Liquiritiae: 0.5-1 g for catarrhal phenomena of the upper respiratory tract; 1.5-3 g for ulcus ventriculi/duodeni.

This section has been translated automatically.

Due to the blood pressure lowering effect, do not prescribe at the same time as diuretics, cardiac glycosides, corticosteroids, laxatives or medicines affecting the electrolyte balance.

This section has been translated automatically.

Severe liver disease, hypertension, existing angina pectoris, terminal renal failure, pregnancy (see also explanations under glycyrrhizin), potassium deficiency. Pregnancy.
No knowledge of the use of liquorice root in children and adolescents under 18 years of age.
Allergy to one of the ingredients

This section has been translated automatically.

Various tea mixtures are offered for the different indications, mostly as combination preparations:

Bladder Kidney Tea Stada® N, Bladder Kidney Tea Uroflux® Tea Infusion Powder, Bronchostad®, Chest and Cough Tea-Stada® N, Buccotean®TF, Dr. Klinger's stomach tea, Fugacid® bladder tea, Fugacid® neurogast tea, urinary tea 400, skin and blood cleansing tea, Heumann bronchial tea Solubifix® N, Heumann stomach tea Solu-Vetan® NG, Kneipp®Gastropressan, gastrointestinal tea, Nieron® bladder and kidney tea VI, Orbis® bladder and kidney tea, Orbis® cough and bronchial tea, Renob® bladder and kidney tea, Solu-Vetan® NG cum Belladonna, Warando® laxative tea

Lakriment Pastilles® (mono-preparation): dosage: 1-1-1 or 2-2-2/day

Externally: Atopiclair®

This section has been translated automatically.

Licorice contains about 20% of the liquorice sugar contained in liquorice.

This section has been translated automatically.

  1. Jung JC et al. (2016) Hepatoprotective effect of licorice, the root of Glycyrrhiza uralensis Fischer, in alcohol-induced fatty liver disease. BMC Complement Altern Med 16:19.
  2. Kamei J et al. (2005) Pharmacokinetic and pharmacodynamic profiles of the antitussive principles of Glycyrrhizae radix (licorice), a main component of the Kampo preparation Bakumondo-to (Mai-men-dong-tang). Eur J Pharmacol 507:163-168.
  3. Sun C et al. (2008) Analysis of glycyrrhizic acid and liquiritin in liquorice root with microwave-assisted micellar extraction and pre -concentration. Phytochem Anal 19:160-163.
  4. Yang XL et al. (2013) Study on in vitro anti-inflammatory activity of total flavonoids from Glycyrrhizae Radix et Rhizoma and its ingredients. Zhongguo Zhong Yao Za Zhi 38:99-104.
  5. Abramovits W et al. (2006) A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS 063 DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 5: 236-244